Reporting recommendations for tumor marker prognostic studies (REMARK): explanation and elaboration
暂无分享,去创建一个
Douglas G Altman | Willi Sauerbrei | Lisa M McShane | W. Sauerbrei | D. Altman | L. McShane | S. Taube | Sheila E Taube
[1] M. Parmar,et al. Association of molecular markers with toxicity outcomes in a randomized trial of chemotherapy for advanced colorectal cancer: the FOCUS trial. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] M. Schmelz,et al. Prognostic criteria for squamous cell cancer of the skin. , 2010, The Journal of surgical research.
[3] W. Sauerbrei,et al. Reporting of prognostic studies of tumour markers: a review of published articles in relation to REMARK guidelines , 2009, British Journal of Cancer.
[4] D. Moher,et al. The Revised CONSORT Statement for Reporting Randomized Trials: Explanation and Elaboration , 2001, Annals of Internal Medicine.
[5] Richard D Riley,et al. A Systematic Review of Molecular and Biological Tumor Markers in Neuroblastoma , 2004, Clinical Cancer Research.
[6] H. Hollema,et al. The ErbB signalling pathway: protein expression and prognostic value in epithelial ovarian cancer , 2008, British Journal of Cancer.
[7] H. White,et al. Logistic regression in the medical literature: standards for use and reporting, with particular attention to one medical domain. , 2001, Journal of clinical epidemiology.
[8] Patrick Royston,et al. Multivariable Model-Building: A Pragmatic Approach to Regression Analysis based on Fractional Polynomials for Modelling Continuous Variables , 2008 .
[9] S. Love,et al. Survival Analysis Part II: Multivariate data analysis – an introduction to concepts and methods , 2003, British Journal of Cancer.
[10] E Marubini,et al. Analysing Survival Data from Clinical Trials and Observational Studies; E. Marubini & M. G. Valsecchi Published by John Wiley & Sons 414 pages ISBN 0-971-93987-0. , 1995, British journal of clinical pharmacology.
[11] T. Stijnen,et al. Review: a gentle introduction to imputation of missing values. , 2006, Journal of clinical epidemiology.
[12] M. Falagas,et al. A systematic review of trends in the methodological quality of randomized controlled trials in various research fields. , 2009, Journal of clinical epidemiology.
[13] W. Scheithauer,et al. Limited Value of CA 19-9 in Predicting Early Treatment Failure in Patients with Advanced Pancreatic Cancer , 2008, Oncology.
[14] S. T. Buckland,et al. An Introduction to the Bootstrap. , 1994 .
[15] Alvan R. Feinstein,et al. Multivariable Analysis: An Introduction , 1996 .
[16] M. Mazumdar,et al. Increased shedding of HU177 correlates with worse prognosis in primary melanoma , 2010, Journal of Translational Medicine.
[17] D G Altman,et al. Prognostic markers in cancer: the evolution of evidence from single studies to meta-analysis, and beyond , 2009, British Journal of Cancer.
[18] Robert Tibshirani,et al. The Elements of Statistical Learning: Data Mining, Inference, and Prediction, 2nd Edition , 2001, Springer Series in Statistics.
[19] M. Caligiuri,et al. Wilms' tumor 1 gene mutations independently predict poor outcome in adults with cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] S. Bentzen. Prognostic factor studies in oncology: osteosarcoma as a clinical example. , 2001, International journal of radiation oncology, biology, physics.
[21] Stephen R Cole,et al. Use of multiple imputation in the epidemiologic literature. , 2008, American journal of epidemiology.
[22] G. Giaccone,et al. Is a patient's self-reported health-related quality of life a prognostic factor for survival in non-small-cell lung cancer patients? A multivariate analysis of prognostic factors of EORTC study 08975. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.
[23] Martin Schumacher,et al. Risk factors for the development of nosocomial pneumonia and mortality on intensive care units: application of competing risks models , 2008, Critical care.
[24] W. Sauerbrei,et al. Dangers of using "optimal" cutpoints in the evaluation of prognostic factors. , 1994, Journal of the National Cancer Institute.
[25] D. G. Altman,et al. Review of survival analyses published in cancer journals. , 1995, British Journal of Cancer.
[26] Carl van Walraven,et al. Time-dependent bias was common in survival analyses published in leading clinical journals. , 2004, Journal of clinical epidemiology.
[27] D. Sargent,et al. End points for adjuvant therapy trials: has the time come to accept disease-free survival as a surrogate end point for overall survival? , 2006, The oncologist.
[28] P. Bossuyt,et al. Reporting bias in diagnostic and prognostic studies: time for action. , 2008, Clinical chemistry.
[29] R. Gray. Weighted analyses for cohort sampling designs , 2009, Lifetime data analysis.
[30] J. Verdebout,et al. Role of Bcl-2 as a prognostic factor for survival in lung cancer: a systematic review of the literature with meta-analysis , 2003, British Journal of Cancer.
[31] P. Quirke,et al. DNA markers predicting benefit from adjuvant fluorouracil in patients with colon cancer: a molecular study , 2002, The Lancet.
[32] L. Akslen,et al. Prognostic impact of alterations in P-cadherin expression and related cell adhesion markers in endometrial cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[33] E. Shpall,et al. Prognostic analysis of tumour angiogenesis, determined by microvessel density and expression of vascular endothelial growth factor, in high-risk primary breast cancer patients treated with high-dose chemotherapy , 2007, British Journal of Cancer.
[34] J. Vandenbroucke. Prospective or retrospective: what's in a name? , 1991, BMJ.
[35] Martin Schumacher,et al. The impact of time‐dependent bias in proportional hazards modelling , 2008, Statistics in medicine.
[36] V. McCormack,et al. Issues in the reporting of epidemiological studies: a survey of recent practice , 2004, BMJ : British Medical Journal.
[37] P W Lavori,et al. Sample-size calculations for the Cox proportional hazards regression model with nonbinary covariates. , 2000, Controlled clinical trials.
[38] Per Kragh Andersen,et al. Competing Risks and Time‐Dependent Covariates , 2009, Biometrical journal. Biometrische Zeitschrift.
[39] John P A Ioannidis,et al. Almost all articles on cancer prognostic markers report statistically significant results. , 2007, European journal of cancer.
[40] J. Foekens,et al. The prognostic value of polymorphonuclear leukocyte elastase in patients with primary breast cancer. , 2003, Cancer research.
[41] J. Coindre,et al. Obvious peritumoral emboli: an elusive prognostic factor reappraised. Multivariate analysis of 1320 node-negative breast cancers. , 1998, European journal of cancer.
[42] F. Harrell,et al. Regression models for prognostic prediction: advantages, problems, and suggested solutions. , 1985, Cancer treatment reports.
[43] D. Seligson,et al. Expression of epithelial membrane protein‐2 is associated with endometrial adenocarcinoma of unfavorable outcome , 2006, Cancer.
[44] David W. Hosmer,et al. Applied Survival Analysis: Regression Modeling of Time-to-Event Data , 2008 .
[45] R. Ceriani,et al. Levels of expression of breast epithelial mucin detected by monoclonal antibody BrE‐3 in breast‐cancer prognosis , 1992, International journal of cancer.
[46] C. Sotiriou,et al. Different prognostic value of cytokeratin-19 mRNA positive circulating tumor cells according to estrogen receptor and HER2 status in early-stage breast cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[47] D. Moher,et al. CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials , 2010, Journal of clinical epidemiology.
[48] D G Altman,et al. Missing covariate data within cancer prognostic studies: a review of current reporting and proposed guidelines , 2004, British Journal of Cancer.
[49] A. Sood,et al. Glucose as a prognostic factor in ovarian carcinoma , 2009, Cancer.
[50] P. Grambsch,et al. Evaluation of sampling strategies for modeling survival of uveal malignant melanoma. , 2003, Investigative ophthalmology & visual science.
[51] James F. Watkins,et al. Analysing Survival Data from Clinical Trials and Observational Studies. , 1995 .
[52] Charles E McCulloch,et al. Relaxing the rule of ten events per variable in logistic and Cox regression. , 2007, American journal of epidemiology.
[53] Per Kragh Andersen,et al. Regression with Linear Predictors , 2010 .
[54] Douglas G Altman,et al. Survival plots of time-to-event outcomes in clinical trials: good practice and pitfalls , 2002, The Lancet.
[55] W. Sauerbrei,et al. Steroid receptors in carcinoma of the breast. Results of immunocytochemical and biochemical determination and their effects on short-term prognosis. , 1994, Analytical and quantitative cytology and histology.
[56] M Schemper,et al. A note on quantifying follow-up in studies of failure time. , 1996, Controlled clinical trials.
[57] S. Assmann,et al. Subgroup analysis and other (mis)uses of baseline data in clinical trials , 2000, The Lancet.
[58] D. Ransohoff. Bias as a threat to the validity of cancer molecular-marker research , 2005, Nature reviews. Cancer.
[59] P. Royston,et al. Selection of important variables and determination of functional form for continuous predictors in multivariable model building , 2007, Statistics in medicine.
[60] Nilanjan Chatterjee,et al. Design and analysis of two‐phase studies with binary outcome applied to Wilms tumour prognosis , 1999 .
[61] Daniel B. Mark,et al. TUTORIAL IN BIOSTATISTICS MULTIVARIABLE PROGNOSTIC MODELS: ISSUES IN DEVELOPING MODELS, EVALUATING ASSUMPTIONS AND ADEQUACY, AND MEASURING AND REDUCING ERRORS , 1996 .
[62] J. Concato,et al. Importance of events per independent variable in proportional hazards regression analysis. II. Accuracy and precision of regression estimates. , 1995, Journal of clinical epidemiology.
[63] James Rochon,et al. Issues in Adjusting for Covariates Arising Postrandomization in Clinical Trials , 1999 .
[64] M Schumacher,et al. Sample size considerations for the evaluation of prognostic factors in survival analysis. , 2000, Statistics in medicine.
[65] F. Montorsi,et al. Nephroureterectomy and segmental ureterectomy in the treatment of invasive upper tract urothelial carcinoma: a population-based study of 2299 patients. , 2009, European journal of cancer.
[66] J. Concato,et al. The Risk of Determining Risk with Multivariable Models , 1993, Annals of Internal Medicine.
[67] M Richard Simon,et al. Design and Analysis of DNA Microarray Investigations , 2004 .
[68] Keith R. Abrams,et al. Evaluating the Quality of Research into a Single Prognostic Biomarker: A Systematic Review and Meta-analysis of 83 Studies of C-Reactive Protein in Stable Coronary Artery Disease , 2010, PLoS medicine.
[69] Douglas G Altman,et al. Dichotomizing continuous predictors in multiple regression: a bad idea , 2006, Statistics in medicine.
[70] W. Sauerbrei,et al. Reporting recommendations for tumor marker prognostic studies (REMARK). , 2005, Journal of the National Cancer Institute.
[71] N. Malats,et al. P53 as a prognostic marker for bladder cancer: a meta-analysis and review. , 2005, The Lancet. Oncology.
[72] William D. Dupont,et al. Statistical Modeling for Biomedical Researchers: A Simple Introduction to the Analysis of Complex Data , 2009 .
[73] D. Ransohoff,et al. Biomarker studies: a call for a comprehensive biomarker study registry , 2011, Nature Reviews Clinical Oncology.
[74] N. Pavlidis,et al. Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial , 2009, Breast Cancer Research and Treatment.
[75] Validation of UBE2C protein as a prognostic marker in node-positive breast cancer , 2009, British Journal of Cancer.
[76] D. Hosmer,et al. Applied Logistic Regression , 1991 .
[77] Leigh Tooth,et al. A review of two journals found that articles using multivariable logistic regression frequently did not report commonly recommended assumptions. , 2004, Journal of clinical epidemiology.
[78] M Egger,et al. Value of flow diagrams in reports of randomized controlled trials. , 2001, JAMA.
[79] D Moher,et al. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. , 2001, Annals of internal medicine.
[80] M. Bonetti,et al. A graphical method to assess treatment-covariate interactions using the Cox model on subsets of the data. , 2000, Statistics in medicine.
[81] S. Pocock,et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies , 2007, The Lancet.
[82] P. Friedman,et al. Circulating tumor cells in HER-2 positive metastatic breast cancer patients treated with trastuzumab and chemotherapy. , 2009, The International journal of biological markers.
[83] M Bracko,et al. S‐phase fraction determined on fine needle aspirates is an independent prognostic factor in breast cancer – a multivariate study of 770 patients , 2008, Cytopathology.
[84] Anthony C. Davison,et al. Bootstrap Methods and Their Application , 1998 .
[85] M. Bracken,et al. Tissue biomarkers for prognosis in cutaneous melanoma: a systematic review and meta-analysis. , 2009, Journal of the National Cancer Institute.
[86] S. Leung,et al. Stromal mast cells in invasive breast cancer are a marker of favourable prognosis: a study of 4,444 cases , 2007, Breast Cancer Research and Treatment.
[87] P. Royston,et al. Regression using fractional polynomials of continuous covariates: parsimonious parametric modelling. , 1994 .
[88] E. Steyerberg. Clinical Prediction Models , 2008, Statistics for Biology and Health.
[89] Sally Hunsberger,et al. Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[90] S. Pocock,et al. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): Explanation and Elaboration , 2007, Annals of Internal Medicine [serial online].
[91] D. Cook,et al. The Completeness of Reporting (CORE) index identifies important deficiencies in observational study conference abstracts. , 2008, Journal of clinical epidemiology.
[92] Nathan L Pace,et al. Independent predictors from stepwise logistic regression may be nothing more than publishable P values. , 2008, Anesthesia and analgesia.
[93] J. Ioannidis. Why Most Discovered True Associations Are Inflated , 2008, Epidemiology.
[94] M. Brundage,et al. Prognostic factors in non-small cell lung cancer: a decade of progress. , 2002, Chest.
[95] John P A Ioannidis,et al. Selective reporting biases in cancer prognostic factor studies. , 2005, Journal of the National Cancer Institute.
[96] Michael A Babyak,et al. What You See May Not Be What You Get: A Brief, Nontechnical Introduction to Overfitting in Regression-Type Models , 2004, Psychosomatic medicine.
[97] J. Lafitte,et al. Role of p53 as a prognostic factor for survival in lung cancer: a systematic review of the literature with a meta-analysis. , 2001, The European respiratory journal.
[98] S. Taube,et al. Standard Reference Material for Her2 Testing: Report of a National Institute of Standards and Technology-sponsored Consensus Workshop , 2003, Applied immunohistochemistry & molecular morphology : AIMM.
[99] W. W. Muir,et al. Regression Diagnostics: Identifying Influential Data and Sources of Collinearity , 1980 .
[100] Michael R Chernick,et al. Bootstrap Methods: A Guide for Practitioners and Researchers , 2007 .
[101] K. Mengersen,et al. Selective Reporting of Adjusted Estimates in Observational Epidemiology Studies: Reasons and Implications for Meta-analyses , 2008, Evaluation & the health professions.
[102] P. Royston,et al. Interactions between treatment and continuous covariates: a step toward individualizing therapy. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[103] Walter C Willett,et al. The search for truth must go beyond statistics. , 2008, Epidemiology.
[104] Z. Trajanoski,et al. Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome , 2006, Science.
[105] Douglas G. Altman,et al. Methodological challenges in the evaluation of prognostic factors in breast cancer. , 1998 .
[106] Michael G Kenward,et al. Multiple imputation: current perspectives , 2007, Statistical methods in medical research.
[107] M. Kenward,et al. Multiple imputation for missing data in epidemiological and clinical research: potential and pitfalls , 2009, BMJ : British Medical Journal.
[108] W. Sauerbrei,et al. Assessment of breast cancer vascularisation by Doppler ultrasound as a prognostic factor of survival. , 2004, Oncology reports.
[109] D. G. Altman,et al. Statistical aspects of prognostic factor studies in oncology. , 1994, British Journal of Cancer.
[110] M. Abrahamowicz,et al. Joint estimation of time‐dependent and non‐linear effects of continuous covariates on survival , 2007, Statistics in medicine.
[111] F. Waldman,et al. Reproducibility of p53 Immunohistochemistry in Bladder Tumors , 2000 .
[112] Richard D Riley,et al. Evidence-Based Assessment and Application of Prognostic Markers: The Long Way from Single Studies to Meta-Analysis , 2006 .
[113] P. Goodwin,et al. Prognostic effects of 25-hydroxyvitamin D levels in early breast cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[114] A. Harris,et al. Cytoplasmic p21WAF1/CIP1 expression is correlated with HER-2/ neu in breast cancer and is an independent predictor of prognosis , 2003, Breast Cancer Research.
[115] J. Ioannidis,et al. Assessment of claims of improved prediction beyond the Framingham risk score. , 2009, JAMA.
[116] Helen M. Moore,et al. Biospecimen Reporting for Improved Study Quality. , 2011, Biopreservation and biobanking.
[117] J. Schneider,et al. Different detection rates of HER-2/NEU overexpression in ovarian carcinoma using two different commercially available detection kits. , 1995, European journal of cancer.
[118] L. Seymour,et al. Clinical Utility of Epidermal Growth Factor Receptor Expression for Selecting Patients with Advanced Non-small Cell Lung Cancer for Treatment with Erlotinib , 2006, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[119] D. Moher,et al. CONSORT 2010 Explanation and Elaboration: updated guidelines for reporting parallel group randomised trials , 2010, BMJ : British Medical Journal.
[120] J. Ioannidis,et al. Systematic Review of the Empirical Evidence of Study Publication Bias and Outcome Reporting Bias , 2008, PloS one.
[121] M Schumacher,et al. Modelling the effects of standard prognostic factors in node-positive breast cancer , 1999, British Journal of Cancer.
[122] Jeremy MG Taylor,et al. Validation of Biomarker-Based Risk Prediction Models , 2008, Clinical Cancer Research.
[123] D G Altman,et al. REporting recommendations for tumour MARKer prognostic studies (REMARK) , 2005, British journal of cancer.
[124] W. Sauerbrei,et al. Confidence intervals for the effect of a prognostic factor after selection of an ‘optimal’ cutpoint , 2004, Statistics in medicine.
[125] M. Ellis,et al. Recommendations for collection and handling of specimens from group breast cancer clinical trials. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[126] M. Hauptmann,et al. Estrogen receptor-alpha phosphorylation at serine-118 and tamoxifen response in breast cancer. , 2009, Journal of the National Cancer Institute.
[127] A Rogier T Donders,et al. Imputation of missing values is superior to complete case analysis and the missing-indicator method in multivariable diagnostic research: a clinical example. , 2006, Journal of clinical epidemiology.
[128] T G Clark,et al. Survival Analysis Part I: Basic concepts and first analyses , 2003, British Journal of Cancer.
[129] D. Altman,et al. Outcome selection bias in meta-analysis , 2005, Statistical methods in medical research.
[130] M. Reiss,et al. Estrogen-dependent prognostic significance of cyclooxygenase-2 expression in early-stage invasive breast cancers treated with breast-conserving surgery and radiation. , 2008, International journal of radiation oncology, biology, physics.
[131] C. Osborne,et al. Randomized, controlled trial of cyclophosphamide, methotrexate, and fluorouracil versus cyclophosphamide, doxorubicin, and fluorouracil with and without tamoxifen for high-risk, node-negative breast cancer: treatment results of Intergroup Protocol INT-0102. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[132] E Biganzoli,et al. Time-dependent relevance of steroid receptors in breast cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[133] J H Lubin,et al. On power and sample size for studying features of the relative odds of disease. , 1990, American journal of epidemiology.
[134] Charles E. McCulloch,et al. Regression Methods in Biostatistics: Linear, Logistic, Survival, and Repeated Measures Models , 2005 .
[135] S. Lagakos. The challenge of subgroup analyses--reporting without distorting. , 2006, The New England journal of medicine.
[136] S. Pocock,et al. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): Explanation and Elaboration , 2007, PLoS medicine.
[137] H. Boshuizen,et al. Multiple imputation of missing blood pressure covariates in survival analysis. , 1999, Statistics in medicine.
[138] M. Dowsett,et al. Current Perspectives on HER2 Testing: A Review of National Testing Guidelines , 2003, Modern Pathology.
[139] Helen M Moore,et al. Biospecimen reporting for improved study quality (BRISQ). , 2011, Journal of proteome research.
[140] D. Moher,et al. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. , 2001, Journal of the American Podiatric Medical Association.
[141] Cathepsin-D in primary breast cancer: prognostic evaluation involving 2810 patients , 1999, British Journal of Cancer.
[142] P C Lambert,et al. Reporting of prognostic markers: current problems and development of guidelines for evidence-based practice in the future , 2003, British Journal of Cancer.
[143] Giovanni Parmigiani,et al. SMAD4 Gene Mutations Are Associated with Poor Prognosis in Pancreatic Cancer , 2009, Clinical Cancer Research.
[144] Douglas G Altman,et al. Interaction revisited: the difference between two estimates , 2003, BMJ : British Medical Journal.
[145] Carl van Walraven,et al. Leave ‘em Alone – Why Continuous Variables Should Be Analyzed as Such , 2008, Neuroepidemiology.
[146] P. Royston,et al. A new approach to modelling interactions between treatment and continuous covariates in clinical trials by using fractional polynomials , 2004, Statistics in medicine.
[147] D G Altman,et al. Survival probabilities (the Kaplan-Meier method) , 1998, BMJ.
[148] Douglas G Altman,et al. Reporting recommendations for tumor marker prognostic studies. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[149] J. Going,et al. Predicting the future: a critical appraisal of cancer prognosis studies , 1999, Histopathology.
[150] John P A Ioannidis,et al. New Prognostic Markers for Outcome of Acute Pancreatitis: Overview of Reporting in 184 Studies , 2011, Pancreas.
[151] P. Sandercock,et al. Progress Review Blood Markers for the Prognosis of Ischemic Stroke A Systematic Review , 2009 .
[152] Wei-Chih Liao,et al. Serum Interleukin-6 Level but not Genotype Predicts Survival after Resection in Stages II and III Gastric Carcinoma , 2008, Clinical Cancer Research.
[153] M Mupparapu,et al. Calcified carotid artery atheroma and stroke: a systematic review. , 2007, Journal of the American Dental Association.
[154] C. Mallows. The Zeroth Problem , 1998 .
[155] Jolanta Lissowska,et al. Loss of antigenicity in stored sections of breast cancer tissue microarrays. , 2004, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.
[156] M. Clench,et al. MALDI-ion mobility separation-mass spectrometry imaging of glucose-regulated protein 78 kDa (Grp78) in human formalin-fixed, paraffin-embedded pancreatic adenocarcinoma tissue sections. , 2009, Journal of proteome research.
[157] M. Pepe,et al. Limitations of the odds ratio in gauging the performance of a diagnostic, prognostic, or screening marker. , 2004, American journal of epidemiology.
[158] Michael W Kattan,et al. Evaluating a New Marker’s Predictive Contribution , 2004, Clinical Cancer Research.
[159] Jacobus Pfisterer,et al. Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: A combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials , 2009, Cancer.
[160] D. Christiani,et al. Vascular Endothelial Growth Factor Polymorphisms and Esophageal Cancer Prognosis , 2009, Clinical Cancer Research.
[161] M. Vijver,et al. Assessment of problems in diagnostic and research immunohistochemistry associated with epitope instability in stored paraffin sections. , 2000 .
[162] J. Ioannidis,et al. Quality of reporting of cancer prognostic marker studies: association with reported prognostic effect. , 2007, Journal of the National Cancer Institute.
[163] S Greenland,et al. Tests for interaction in epidemiologic studies: a review and a study of power. , 1983, Statistics in medicine.
[164] W. Sauerbrei,et al. Identification of clinically useful cancer prognostic factors: what are we missing? , 2005, Journal of the National Cancer Institute.
[165] I. Floriani,et al. Prognostic value of circulating chromogranin A and soluble tumor necrosis factor receptors in advanced nonsmall cell lung cancer , 2007, Cancer.
[166] M. Loda,et al. p27Kip1 in Stage III Colon Cancer: Implications for Outcome following Adjuvant Chemotherapy in Cancer and Leukemia Group B Protocol 89803 , 2009, Clinical Cancer Research.
[167] J. Ioannidis,et al. The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration , 2009, Annals of Internal Medicine [serial online].
[168] Soonmyung Paik,et al. Use of archived specimens in evaluation of prognostic and predictive biomarkers. , 2009, Journal of the National Cancer Institute.
[169] W. Sauerbrei,et al. Multivariate Analysis of Prognostic Factors in Patients with Glioblastoma , 2003, Strahlentherapie und Onkologie.
[170] L. Murphy,et al. Steroid Receptor RNA Activator Protein (SRAP): a potential new prognostic marker for estrogen receptor-positive/node-negative/younger breast cancer patients , 2009, Breast Cancer Research.
[171] W. Sauerbrei,et al. Cellular DNA content and survival in advanced ovarian carcinoma , 1994, Cancer.
[172] S. Martino,et al. Nitric Oxide Synthase Variants and Disease-Free Survival among Treated and Untreated Breast Cancer Patients in a Southwest Oncology Group Clinical Trial , 2009, Clinical Cancer Research.
[173] Douglas G. Altman,et al. Practical statistics for medical research , 1990 .
[174] Yvonne Vergouwe,et al. Prognosis and prognostic research: validating a prognostic model , 2009, BMJ : British Medical Journal.
[175] S. Taneja,et al. Neutral Endopeptidase Protein Expression and Prognosis in Localized Prostate Cancer , 2004, Clinical Cancer Research.
[176] R. Simon,et al. Statistical Methods for the Analysis of Prognostic Factor Studies , 2003 .
[177] J. Ioannidis,et al. Predictive ability of DNA microarrays for cancer outcomes and correlates: an empirical assessment , 2003, The Lancet.
[178] Andrew J Vickers,et al. Cutpoints in clinical chemistry: time for fundamental reassessment. , 2009, Clinical chemistry.
[179] Young Tae Kim,et al. Diagnostic and Prognostic Impact of Osteopontin Expression in Endometrial Cancer , 2009, Cancer investigation.
[180] S. Groshen,et al. Hypermethylated APC DNA in plasma and prognosis of patients with esophageal adenocarcinoma. , 2000, Journal of the National Cancer Institute.
[181] Robert Gray,et al. Flexible Methods for Analyzing Survival Data Using Splines, with Applications to Breast Cancer Prognosis , 1992 .
[182] Robin L. Jones,et al. The prognostic significance of Ki67 before and after neoadjuvant chemotherapy in breast cancer , 2009, Breast Cancer Research and Treatment.
[183] Frank E. Harrell,et al. Regression Modeling Strategies: With Applications to Linear Models, Logistic Regression, and Survival Analysis , 2001 .
[184] P. Grambsch,et al. Modeling Survival Data: Extending the Cox Model , 2000 .
[185] D G Altman,et al. What do we mean by validating a prognostic model? , 2000, Statistics in medicine.
[186] J Carpenter,et al. Bootstrap confidence intervals: when, which, what? A practical guide for medical statisticians. , 2000, Statistics in medicine.
[187] A. Matakidou,et al. Thymidylate synthase expression and prognosis in colorectal cancer: a systematic review and meta-analysis. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[188] Douglas G Altman,et al. Quantification of the completeness of follow-up , 2002, The Lancet.
[189] P. Royston,et al. Is treatment with interferon-α effective in all patients with metastatic renal carcinoma? A new approach to the investigation of interactions , 2004, British Journal of Cancer.
[190] D. Slamon,et al. Sensitivity of HER-2/neu antibodies in archival tissue samples: potential source of error in immunohistochemical studies of oncogene expression. , 1994, Cancer research.
[191] Chris Chatfield,et al. Confessions of a pragmatic statistician , 2002 .
[192] D G Altman,et al. Survival Analysis Part IV: Further concepts and methods in survival analysis , 2003, British Journal of Cancer.
[193] L. Fisher,et al. Time-dependent covariates in the Cox proportional-hazards regression model. , 1999, Annual review of public health.
[194] G. Grunkemeier,et al. Measuring follow-up completeness. , 2008, The Annals of thoracic surgery.
[195] W. Sauerbrei. Prognostic factors. Confusion caused by bad quality design, analysis and reporting of many studies. , 2005, Advances in oto-rhino-laryngology.
[196] P. Royston,et al. A New Proposal for Multivariable Modelling of Time‐Varying Effects in Survival Data Based on Fractional Polynomial Time‐Transformation , 2007, Biometrical journal. Biometrische Zeitschrift.
[197] S. Love,et al. Survival Analysis Part III: Multivariate data analysis – choosing a model and assessing its adequacy and fit , 2003, British Journal of Cancer.
[198] C. Ulrich,et al. Elevated biomarkers of inflammation are associated with reduced survival among breast cancer patients. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[199] P. Royston,et al. Flexible parametric proportional‐hazards and proportional‐odds models for censored survival data, with application to prognostic modelling and estimation of treatment effects , 2002, Statistics in medicine.
[200] H. Moch,et al. Down regulation of E-Cadherin (ECAD) - a predictor for occult metastatic disease in sentinel node biopsy of early squamous cell carcinomas of the oral cavity and oropharynx , 2011, BMC Cancer.
[201] H. Höfler,et al. CyclinD1 and interleukin-1 receptor antagonist polymorphisms are associated with prognosis in neoadjuvant-treated gastric carcinoma. , 2009, European journal of cancer.
[202] W Sauerbrei,et al. Influence of model-building strategies on the results of a case-control study. , 1993, Statistics in medicine.
[203] R. Houlston,et al. A prospective, blinded analysis of thymidylate synthase and p53 expression as prognostic markers in the adjuvant treatment of colorectal cancer. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.
[204] A. Rosenwald,et al. Five-gene model to predict survival in mantle-cell lymphoma using frozen or formalin-fixed, paraffin-embedded tissue. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[205] S. Mathoulin-Pélissier,et al. Survival end point reporting in randomized cancer clinical trials: a review of major journals. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[206] Willi Sauerbrei,et al. The Use of Resampling Methods to Simplify Regression Models in Medical Statistics , 1999 .
[207] S. Manikandan. Preparing to analyse data , 2010, Journal of pharmacology & pharmacotherapeutics.
[208] Boris Freidlin,et al. Randomized clinical trials with biomarkers: design issues. , 2010, Journal of the National Cancer Institute.
[209] Guido Schwarzer,et al. Prognostic Factor Studies , 2012 .